On the Alert for Cytokine Storm: Immunopathology in COVID-19

Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.

Abstract

Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Betacoronavirus
  • Biomarkers
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy
  • Cytokine Release Syndrome / diagnosis
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / virology*
  • Early Medical Intervention
  • Humans
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy
  • SARS-CoV-2

Substances

  • Anti-Inflammatory Agents
  • Biomarkers